<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00262054</url>
  </required_header>
  <id_info>
    <org_study_id>GE IDE No. A01005</org_study_id>
    <secondary_id>KKF 1.1-05</secondary_id>
    <nct_id>NCT00262054</nct_id>
  </id_info>
  <brief_title>Un-fractionated Heparin Versus Bivalirudin During Percutaneous Coronary Interventions (PCI) (ISAR-REACT-3)</brief_title>
  <official_title>Prospective, Randomized, Double-Blind, Active-Controlled, Multicenter Trial of Bivalirudin and Un-fractionated Heparin in Patients Undergoing Percutaneous Coronary Interventions. ISAR-REACT-3</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deutsches Herzzentrum Muenchen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Deutsches Herzzentrum Muenchen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether bivalirudin given during PCI is associated
      with better outcomes compared to un-fractionated heparin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thrombin plays a major role in acute coronary artery occlusions during percutaneous coronary
      interventions. Unfractionated heparin has been traditionally used during invasive coronary
      procedures to reduce the risk of thrombotic occlusion. Bivalirudin, a direct antithrombin
      inhibitor, has several advantages over unfractionated heparin: it acts independently of
      antithrombin and inhibits both free and clot-bound thrombin; it is not neutralized by
      circulating inhibitors; exhibits consistent dose-response characteristics, and does not cause
      thrombocytopenia. Previous studies have shown that use of bivalirudin among patients
      undergoing percutaneous coronary interventions is associated with better outcomes (death,
      myocardial infarction, urgent repeat revascularization or in-hospital major bleeding) as
      compared with unfractionated heparin and adjunctive use of glycoprotein IIb/IIIa platelet
      receptor inhibitors. However, previous studies have included patients treated with plain
      balloon angioplasty or stenting after inadequate pre-treatment with thienopyridines
      (ticlopidine or clopidogrel). Recent guidelines recommend that all patients undergoing
      percutaneous coronary interventions must receive a loading dose of 300 -600 mg of
      clopidogrel. A 600 mg loading dose of clopidogrel eliminates the need for glycoprotein
      IIb/IIIa platelet receptor inhibitors in adjunct to heparin. According to existing evidence
      antithrombotic regimens based on either bivalirudin or pre-treatment with 600 mg of
      clopidogrel in addition to UFH intraprocedurally, are effective strategies to reduce ischemic
      and hemorrhagic complications in patients with coronary artery disease undergoing PCI. At
      present, it is not known whether bivalirudin is superior to UHF in patients who have been
      optimally pre-treated with a loading dose of clopidogrel.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Composite rate of death, myocardial infarction (MI),urgent target vessel revascularization (TVR) within 30 days or in-hospital major bleeding</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Composite rate of death, MI or urgent TVR within 30 days</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composite rate of death, MI or TVR at 1 year</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4570</enrollment>
  <condition>Coronary Disease</condition>
  <condition>Angina Pectoris</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>bivalirudin is to be administered as an intravenous bolus of 0.75 mg/kg prior to the start of the intervention, followed by infusion of 1.75 mg/kg per hour for the duration of the procedure.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>UFH given as an intravenous bolus of 140 units/kg. Double blinding will be maintained by using a double-dummy technique consisting of identical UFH and bivalirudin syringes and bivalirudin or placebo infusion bags.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bivalirudin</intervention_name>
    <description>bivalirudin to be administered as an intravenous bolus of 0.75 mg/kg prior to the start of the intervention, followed by infusion of 1.75 mg/kg per hour for the duration of the procedure.</description>
    <arm_group_label>A</arm_group_label>
    <other_name>ReoPro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Un-fractionated heparin</intervention_name>
    <description>UFH is given as an intravenous bolus of 140 units/kg followed by infusion of placebo 1.75 mg/kg per hour for the duration of the procedure.</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients older than 18 years of age to undergo PCI

          -  Clopidogrel loading at least 2 hrs prior to PCI according to the PCI guidelines

          -  Informed, written consent

        Exclusion Criteria:

          -  Recent ST-elevation myocardial infarction within the last 48 hours

          -  Cardiogenic shock

          -  ACS and positive biomarkers (Troponin T &gt; 0.03 Âµg/L)

          -  Malignancies or other comorbid conditions (for example severe liver, renal and
             pancreatic disease) with life expectancy less than one year or that may result in
             protocol non-compliance

          -  Active bleeding; bleeding diathesis

          -  History of gastrointestinal or genitourinary bleeding within the last 6 weeks

          -  Presence of diseases which have a high probability of vascular lesions and subsequent
             bleeding such as active gastric ulcer or active ulcerous colitis

          -  Recent trauma or major surgery in the last month

          -  Ophthalmic surgery or brain surgery in the last month

          -  Retinopathies or vitreous body bleeding in the last month

          -  History of intracranial bleeding or structural abnormalities (for example aneurysm of
             cerebral arteries)

          -  Suspected aortic dissection; pericarditis and subacute bacterial endocarditis

          -  Patient's refusal to blood transfusion

          -  Oral anticoagulation therapy with coumarin derivative within the last 7 days

          -  Treatment with UFH within 6 hours or low-molecular weight heparin within 8 hours
             before randomization

          -  Treatment with bivalirudin within 24 hours before randomization

          -  Severe uncontrolled hypertension &gt;180/110 mmHg unresponsive to therapy

          -  Planned staged PCI procedure within 30 days from index procedure or prior PCI within
             the last 30 days

          -  Relevant hematologic deviations:hemoglobin &lt; 100 g/L; platelet count &lt; 100 x 109 /L

          -  Glomerular filtration rate (GFR) &lt; 30 ml/min or serum creatinine &gt; 30 mg/L or
             dependence on renal dialysis

          -  Known allergy to the study medications: aspirin, clopidogrel, UFH, bivalirudin;
             stainless steel; true anaphylaxis after prior exposure to contrast media

          -  Known heparin-induced thrombocytopenia (Typ II)

          -  Previous enrollment in this trial

          -  Pregnancy (present, suspected or planned) or positive pregnancy test

          -  Spinal, peridural and epidural anesthesia

          -  Patient's inability to fully cooperate with the study protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert Schomig, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Deutsches Herzzentrum Muenchen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Adnan Kastrati, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Deutsches Herzzentrum Muenchen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Franz-Josef Neumann, MD</last_name>
    <role>Study Director</role>
    <affiliation>Herz-Zentrum Bad Krozingen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Herz-Zentrum</name>
      <address>
        <city>Bad Krozingen</city>
        <zip>79189</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Segeberger Kliniken</name>
      <address>
        <city>Bad Segeberg</city>
        <zip>23795</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Muenchen</name>
      <address>
        <city>Munich</city>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>First Medizinische Klinik, Klinikum rechts der Isar</name>
      <address>
        <city>Munich</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Verstraete M. Direct thrombin inhibitors: appraisal of the antithrombotic/hemorrhagic balance. Thromb Haemost. 1997 Jul;78(1):357-63. Review.</citation>
    <PMID>9198179</PMID>
  </reference>
  <reference>
    <citation>Lincoff AM, Bittl JA, Harrington RA, Feit F, Kleiman NS, Jackman JD, Sarembock IJ, Cohen DJ, Spriggs D, Ebrahimi R, Keren G, Carr J, Cohen EA, Betriu A, Desmet W, Kereiakes DJ, Rutsch W, Wilcox RG, de Feyter PJ, Vahanian A, Topol EJ; REPLACE-2 Investigators. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA. 2003 Feb 19;289(7):853-63. Erratum in: JAMA. 2003 Apr 2;289(13):1638.</citation>
    <PMID>12588269</PMID>
  </reference>
  <reference>
    <citation>Silber S, Albertsson P, AvilÃ©s FF, Camici PG, Colombo A, Hamm C, JÃ¸rgensen E, Marco J, Nordrehaug JE, Ruzyllo W, Urban P, Stone GW, Wijns W; Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology. Eur Heart J. 2005 Apr;26(8):804-47. Epub 2005 Mar 15.</citation>
    <PMID>15769784</PMID>
  </reference>
  <reference>
    <citation>Kastrati A, Mehilli J, SchÃ¼hlen H, Dirschinger J, Dotzer F, ten Berg JM, Neumann FJ, Bollwein H, Volmer C, Gawaz M, Berger PB, SchÃ¶mig A; Intracoronary Stenting and Antithrombotic Regimen-Rapid Early Action for Coronary Treatment Study Investigators. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med. 2004 Jan 15;350(3):232-8.</citation>
    <PMID>14724302</PMID>
  </reference>
  <results_reference>
    <citation>Schulz S, Mehilli J, Ndrepepa G, Neumann FJ, Birkmeier KA, Kufner S, Richardt G, Berger PB, SchÃ¶mig A, Kastrati A; Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT) 3 Trial Investigators. Bivalirudin vs. unfractionated heparin during percutaneous coronary interventions in patients with stable and unstable angina pectoris: 1-year results of the ISAR-REACT 3 trial. Eur Heart J. 2010 Mar;31(5):582-7. doi: 10.1093/eurheartj/ehq008. Epub 2010 Feb 11.</citation>
    <PMID>20150324</PMID>
  </results_reference>
  <results_reference>
    <citation>Kastrati A, Neumann FJ, Mehilli J, Byrne RA, Iijima R, BÃ¼ttner HJ, Khattab AA, Schulz S, Blankenship JC, Pache J, Minners J, Seyfarth M, Graf I, Skelding KA, Dirschinger J, Richardt G, Berger PB, SchÃ¶mig A; ISAR-REACT 3 Trial Investigators. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med. 2008 Aug 14;359(7):688-96. doi: 10.1056/NEJMoa0802944. Erratum in: N Engl J Med. 2008 Aug 28;359(9):983.</citation>
    <PMID>18703471</PMID>
  </results_reference>
  <verification_date>August 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 5, 2005</study_first_submitted>
  <study_first_submitted_qc>December 5, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2005</study_first_posted>
  <last_update_submitted>March 12, 2010</last_update_submitted>
  <last_update_submitted_qc>March 12, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2010</last_update_posted>
  <responsible_party>
    <name_title>Prof. A. SchÃ¶mig</name_title>
    <organization>Deutsches Herzzentrum Munich</organization>
  </responsible_party>
  <keyword>coronary disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Angina Pectoris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Bivalirudin</mesh_term>
    <mesh_term>Heparin</mesh_term>
    <mesh_term>Hirudins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

